Beta-Blockers, Left and Right Ventricular Function, and In-Vivo Calcium Influx in Muscular Dystrophy Cardiomyopathy

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Blain, Alison ^a   Greally, Elizabeth ^a   Laval, Steve ^a   Blamire, Andrew ^a   Straub, Volker ^a   MacGowan, Guy A ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; MANGANESE CHLORIDE; METOPROLOL; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CALCIUM TRANSPORT; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE METABOLISM; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HEART RIGHT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART WEIGHT; IN VIVO STUDY; LIMB GIRDLE MUSCULAR DYSTROPHY; MALE; MOUSE; NONHUMAN; TREATMENT OUTCOME; WILD TYPE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BODY WEIGHT; CALCIUM; CARDIOMYOPATHIES; ION TRANSPORT; MALE; METOPROLOL; MICE; MICE, INBRED MDX; MICE, KNOCKOUT; MUSCULAR DYSTROPHIES; ORGAN SIZE; SARCOGLYCANS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 84874260796     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057260     Document Type: Article

References (25)

1. Bushby K, Muntoni F, Bourke JP, (2003) 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden,. The Netherlands.Vol. 13pp: 166-172.
2. Finsterer J, Stöllberger C, (2003) The heart in human dystrophinopathies. Cardiology 99: 1-19 doi:10.1159/000068446.
3. Politano L, Nigro V, Passamano L, Petretta V, Comi LI, et al. (2001) Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 11: 178-185.
4. Packer M, Coats AJ, Fowler MB, Katus HA, KRUM H, et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651-1658 doi:10.1056/NEJM200105313442201.
5. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, et al. (2005) Genetic Predictors and Remodeling of Dilated Cardiomyopathy in Muscular Dystrophy. Circulation 112: 2799-2804 doi:10.1161/CIRCULATIONAHA.104.528281.
6. Bauer R, Blain A, Greally E, Bushby K, Lochmüller H, et al. (2010) Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy. Eur J Heart Fail 12: 1163-1170 doi:10.1093/eurjhf/hfq129.
7. Williams IA, Allen DG, (2007) Intracellular calcium handling in ventricular myocytes from mdx mice. American Journal of Physiology- Heart and Circulatory Physiology 292: H846-H855 doi:10.1152/ajpheart.00688.2006.
8. Hu TC, Pautler RG, MacGowan GA, Koretsky AP, (2001) Manganese-enhanced MRI of mouse heart during changes in inotropy. Magn Reson Med 46: 884-890.
9. Bauer R, Blain A, Greally E, Lochmüller H, Bushby K, et al. (2010) Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. Neuromuscul Disord 20: 21-28 doi:10.1016/j.nmd.2009.10.003.
10. Bauer R, Straub V, Blain A, Bushby K, MacGowan GA, (2009) Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 11: 463-471 doi:10.1093/eurjhf/hfp028.
11. Bauer R, MacGowan GA, Blain A, Bushby K, Straub V, (2008) Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy. Cardiovascular Research 79: 652-661 doi:10.1093/cvr/cvn131.
12. Coral-Vazquez R, Cohn R, Moore S, Hill J, (1999) Disruption of the Sarcoglycan-Sarcospan Complex in Vascular Smooth Muscle: A Novel Mechanism for Cardiomyopathy and Muscular Dystrophy. Cell 98: 465-74 doi:10.1016/S0092-8674(00)81975-3.
13. Greally E, Davison BJ, Blain A, Laval S, Blamire A, Straub V, MacGowan GA (2013) Heterogeneous abnormalities of in-vivo left ventricular calcium influx and function in mouse models of muscular dystrophy cardiomyopathy. J Cardiovasc Magn Reson. Jan 16;15(1):4. [Epub ahead of print].
14. Di Salvo T, Mathier M, Semigran M, (1995) Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 25: 1143-53.
15. Melacini P, Fanin M, Danieli GA, Villanova C, Martinello F, et al. (1996) Myocardial Involvement Is Very Frequent Among Patients Affected With Subclinical Becker's Muscular Dystrophy. Circulation 94: 3168-75.
16. Melacini P, Fanin M, Danieli GA, Fasoli G, Villanova C, et al. (1993) Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol 22: 1927-1934.
17. Stuckey DJ, Carr CA, Camelliti P, Tyler DJ, Davies KE, et al. (2012) In vivo MRI characterization of progressive cardiac dysfunction in the mdx mouse model of muscular dystrophy. PLoS ONE 7: e28569 doi:10.1371/journal.pone.0028569.
18. MacGowan GA, Schueler S, (2012) Right heart failure after left ventricular assist device implantation: early and late. Curr Opin Cardiol 27: 296-300 doi:10.1097/HCO.0b013e3283511e60.
19. MacGowan GA, Rager J, Shroff SG, Mathier MA, (2005) In vivo alpha-adrenergic responses and troponin I phosphorylation: anesthesia interactions. J Appl Physiol 98: 1163-1170 doi:10.1152/japplphysiol.00959.2004.
20. Jacoby C, Molojavyi A, Flogel U, Merx M, Ding Z, et al. (2006) Direct comparison of magnetic resonance imaging and conductance microcatheter in the evaluation of left ventricular function in mice. Basic Res Cardiol 101: 87-95 doi:10.1007/s00395-005-0542-7.
21. Winter E, Grauss R, Atsma D (2008) Left ventricular function in the post-infarct failing mouse heart by magnetic resonance imaging and conductance catheter: a comparative analysis. Acta Physiol (Oxf). 194(2):111-22.
22. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, et al. (2005) Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 436: 1025-1029 doi:10.1038/nature03844.
23. Sussman MA, (1998) Prevention of Cardiac Hypertrophy in Mice by Calcineurin Inhibition. Science 281: 1690-1693 doi:10.1126/science.281.5383.1690.
24. Williams IA, Allen DG, (2007) The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 292: H846-55.
25. Fraysse B, Nagi SM, Boher B, Ragot H, Lainé J, et al. (2010) Ca2+ overload and mitochondrial permeability transition pore activation in living delta-sarcoglycan-deficient cardiomyocytes. Am J Physiol, Cell Physiol 299: C706-C713 doi:10.1152/ajpcell.00545.2009.